Related Experiment Video
Updated: Aug 23, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death: a double edged sword
Loren Michel1, Robert Benezra, Elena Diaz-Rodriguez
1Department of Medicine, Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Abstract:
The failure of cell cycle regulatory checkpoints is a common event in human cancer. Defects at the G(1)-S transition have been widely characterized, but only more recently has aberrant checkpoint signaling during mitotic progression been identified as playing a role in cancer. The metaphase to anaphase transition is regulated by multiple proteins that together comprise the mitotic checkpoint. Previously it has been shown that loss of one copy of MAD2, a mitotic checkpoint gene, results in aneuploidy and tumorigenesis arising from chromosome missegregation. More recently and quite surprisingly, MAD2 has been demonstrated to be an essential gene even in tumor cells such that near complete elimination of this protein from cancer cells results in p53 independent cell death. This is the first identification of a haploinsufficient tumor suppressor gene that is also required for tumor cell survival, and suggests that targeting this checkpoint in cancer might be a viable therapeutic strategy.
Insights
Checkpoint gene MAD2 loss causes cancer and cell death. Targeting this gene offers a potential cancer therapy strategy by exploiting its dual role in tumor suppression and survival.
Area of Science:
- Oncology
- Cell Biology
- Genetics
Background:
- Cell cycle checkpoints are crucial for preventing cancer.
- While G(1)-S transition defects are known, mitotic progression errors are increasingly recognized in cancer.
- The mitotic checkpoint, particularly the metaphase to anaphase transition, is vital for genomic stability.
Purpose of the Study:
- To investigate the role of the MAD2 gene in cancer.
- To explore MAD2's function in mitotic progression and its implications for tumor development.
- To assess MAD2 as a potential therapeutic target in cancer treatment.
Main Methods:
- Analysis of MAD2 gene copy loss effects on aneuploidy and tumorigenesis.
- Evaluation of MAD2's essentiality in cancer cells.
- Assessment of cell death pathways following MAD2 elimination.
Main Results:
- Loss of one MAD2 copy leads to aneuploidy and tumors.
- MAD2 is essential for cancer cell survival, independent of p53.
- Near-complete MAD2 elimination induces p53-independent cell death.
Conclusions:
- MAD2 is a novel haploinsufficient tumor suppressor gene critical for cancer cell survival.
- Targeting the mitotic checkpoint, specifically MAD2, presents a promising therapeutic avenue for cancer.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Mitogens and the Cell Cycle
Mitogens and the Cell Cycle
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
